ATE374783T1 - ßALPHA1-UNTEREINHEIT DES NATRIUMKANALS, POLYPEPTIDE DAVON UND DEREN VERWENDUNG ZUR BEHANDLUNG VON GENERALISIERTER EPILEPSIE MIT FIEBERANFÄLLEN PLUS ß - Google Patents

ßALPHA1-UNTEREINHEIT DES NATRIUMKANALS, POLYPEPTIDE DAVON UND DEREN VERWENDUNG ZUR BEHANDLUNG VON GENERALISIERTER EPILEPSIE MIT FIEBERANFÄLLEN PLUS ß

Info

Publication number
ATE374783T1
ATE374783T1 AT01271383T AT01271383T ATE374783T1 AT E374783 T1 ATE374783 T1 AT E374783T1 AT 01271383 T AT01271383 T AT 01271383T AT 01271383 T AT01271383 T AT 01271383T AT E374783 T1 ATE374783 T1 AT E374783T1
Authority
AT
Austria
Prior art keywords
subunit
polypeptides
ßalpha1
plus
treatment
Prior art date
Application number
AT01271383T
Other languages
English (en)
Inventor
Robyn Wallace
John Mulley
Samuel Berkovic
Original Assignee
Bionomics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionomics Ltd filed Critical Bionomics Ltd
Application granted granted Critical
Publication of ATE374783T1 publication Critical patent/ATE374783T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT01271383T 2000-12-20 2001-12-20 ßALPHA1-UNTEREINHEIT DES NATRIUMKANALS, POLYPEPTIDE DAVON UND DEREN VERWENDUNG ZUR BEHANDLUNG VON GENERALISIERTER EPILEPSIE MIT FIEBERANFÄLLEN PLUS ß ATE374783T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPR2203A AUPR220300A0 (en) 2000-12-20 2000-12-20 New epilepsy gene

Publications (1)

Publication Number Publication Date
ATE374783T1 true ATE374783T1 (de) 2007-10-15

Family

ID=3826237

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01271383T ATE374783T1 (de) 2000-12-20 2001-12-20 ßALPHA1-UNTEREINHEIT DES NATRIUMKANALS, POLYPEPTIDE DAVON UND DEREN VERWENDUNG ZUR BEHANDLUNG VON GENERALISIERTER EPILEPSIE MIT FIEBERANFÄLLEN PLUS ß

Country Status (9)

Country Link
US (1) US7078515B2 (de)
EP (2) EP1351968B1 (de)
JP (1) JP4204317B2 (de)
AT (1) ATE374783T1 (de)
AU (1) AUPR220300A0 (de)
CA (2) CA2714357C (de)
DE (1) DE60130798D1 (de)
NZ (2) NZ541915A (de)
WO (1) WO2002050096A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001038564A2 (en) * 1999-11-26 2001-05-31 Mcgill University Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
ATE373089T1 (de) * 2001-07-18 2007-09-15 Bionomics Ltd Mutationen in ionenkanälen
US7282336B2 (en) * 2001-07-18 2007-10-16 Bionomics Limited Method of diagnosing epilepsy
US7709225B2 (en) * 2001-07-18 2010-05-04 Bionomics Limited Nucleic acids encoding mutations in sodium channels related to epilepsy
AU2003904154A0 (en) * 2003-08-07 2003-08-21 Bionomics Limited Mutations in ion channels
US7125676B2 (en) 2002-02-25 2006-10-24 Vanderbilt University Expression system for human brain-specific voltage-gated sodium channel, type 1
AU2003901425A0 (en) * 2003-03-27 2003-04-10 Bionomics Limited A diagnostic method for epilepsy
AU2004263548B2 (en) * 2003-08-07 2007-09-13 Bionomics Limited Mutations in ion channels
NZ564892A (en) * 2005-06-16 2011-10-28 Bionomics Ltd Methods of treatment, and diagnosis of epilepsy by detecting a D674G mutation in the SCN1A gene
CN101229183B (zh) * 2008-01-17 2010-11-24 周锡漳 一种核糖核酸降解片断复合物及其应用
CN101229184B (zh) * 2008-01-17 2010-08-11 周锡漳 一种脱氧核糖核酸降解片段复合物及其制备药物的应用
US20120283116A1 (en) 2009-09-11 2012-11-08 Leppert Mark F Mutant Sodium Channel Nav1.7 and Methods Related Thereto
EP2770325A1 (de) 2013-02-26 2014-08-27 Institut du Cerveau et de la Moelle Epiniere-ICM Mutationen von DEPDC5 zur Diagnose von epileptischen Funktionsstörungen, Erkrankungen oder Leiden
KR20190086709A (ko) * 2016-11-22 2019-07-23 오비드 테라퓨틱스 인크. 가복사돌로 주의력 결핍/과잉행동 장애를 치료하는 방법들
CN114957445B (zh) * 2022-05-31 2023-09-19 陕西脉元生物科技有限公司 一种nmdar nr1亚基、nmdar的突变体及其构建方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001038564A2 (en) * 1999-11-26 2001-05-31 Mcgill University Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
EP1474176A4 (de) * 2001-11-26 2005-06-15 Bristol Myers Squibb Co Neuer menschlicher g-protein-gekoppelter rezeptor hgprbmy31 sowie varianten davon und verwendungsverfahren dafür
AU2003901425A0 (en) 2003-03-27 2003-04-10 Bionomics Limited A diagnostic method for epilepsy

Also Published As

Publication number Publication date
US7078515B2 (en) 2006-07-18
CA2431891A1 (en) 2002-06-27
EP1351968B1 (de) 2007-10-03
NZ526814A (en) 2006-05-26
WO2002050096A1 (en) 2002-06-27
JP2004515252A (ja) 2004-05-27
DE60130798D1 (de) 2007-11-15
CA2714357C (en) 2013-11-12
CA2431891C (en) 2013-01-29
EP1837342A2 (de) 2007-09-26
US20040110706A1 (en) 2004-06-10
EP1351968A1 (de) 2003-10-15
AUPR220300A0 (en) 2001-01-25
NZ541915A (en) 2007-05-31
EP1837342A3 (de) 2007-12-19
EP1351968A4 (de) 2004-04-28
JP4204317B2 (ja) 2009-01-07
CA2714357A1 (en) 2002-06-27

Similar Documents

Publication Publication Date Title
ATE374783T1 (de) ßALPHA1-UNTEREINHEIT DES NATRIUMKANALS, POLYPEPTIDE DAVON UND DEREN VERWENDUNG ZUR BEHANDLUNG VON GENERALISIERTER EPILEPSIE MIT FIEBERANFÄLLEN PLUS ß
PL397846A1 (pl) Leczenie zaburzeń związanych z TNFα
DK0927024T3 (da) Indretning og fremgangsmåde til behandling af öjensygdomme
MY130489A (en) Substituted aryl 1, 4-pyrazine derivatives
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
DE60020613D1 (de) (S,S)-Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
ATE389649T1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
AU2002343557A1 (en) Substituted aryl 1,4-pyrazine derivatives
IS6560A (is) Lyfjasamsetning fyrir meðhöndlun á bráðum, þrálátum sársauka og/eða taugakerfissársauka og mígreni
ATE211392T1 (de) Verwendung des glialen, neurotrophen faktors (gdnf) zur behandlung von gehörstörungen
ATE515513T1 (de) Behandlung von fibrose durch antagonismus zwischen il-13 und il-13-rezeptorketten
DE60219793D1 (de) Methode zur behandlung von zytokinvermittelten erkrankungen
WO2004019884A3 (en) Agents and methods for enhancing bone formation
ATE384699T1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
ATE276245T1 (de) Indolderivate und deren verwendung zur behandlung von u.a. osteoporosis
DE69906671D1 (de) Substituierte 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanone, deren Verwendung zur Behandlung von Erkrankungen des zentralen und periphären Nervensystems und diese enthaltende pharmazeutische Zusammensetzungen
BRPI0313792B8 (pt) utilização de proteína de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento
DK1228028T3 (da) Hydroxyicosatetraenoatsalte, præparater og fremgangsmåder til anvendelse til behandling af öjentörhedslidelser
ATE534635T1 (de) N-pyrazinyl-phenylsulfonamide und deren verwendung zur behandlung von durch chemokine vermittelten krankheiten
DE69833645D1 (de) Neue therapeutische kombinationen aus mirtazapin und antipsychotika, zur behandlung oder prophylaxe von psychotischen störungen
DK1123414T3 (da) Antisense-modulering af integrin alpha 4.ekspression
DK1408976T3 (da) Behandling af ADHD (Attention deficit hyperactivity disorder)
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties